Status:
ACTIVE_NOT_RECRUITING
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborating Sponsors:
Roche Diagnostics GmbH
University of Glasgow
Conditions:
Cancer
Cardiotoxicity
Eligibility:
All Genders
18+ years
Brief Summary
The advent of immunotherapy (immune checkpoint inhibitors \[ICI\]) has been an extremely important advancement for cancer treatment in recent decades. The anti-cancer effects of these agents is profou...
Eligibility Criteria
Inclusion
- Patients with cancer who are planned for treatment with ICI or VEGFI, including combination therapy
- ≥6 months predicted survival
- Age ≥18 years
Exclusion
- Patients who are unable or unwilling to provide valid consent for the study
- Patients with diabetes who are on oral anti-diabetic treatment or insulin at baseline
- patients who have exposure to either immune checkpoint inhibitor or VEGF inhibitor in the 12 months before enrolment
Key Trial Info
Start Date :
August 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 20 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06597045
Start Date
August 30 2022
End Date
November 20 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G120YN